Nautilus Biotechnolgy, Inc. ( (NAUT) ) has released its Q2 earnings. Here is a breakdown of the information Nautilus Biotechnolgy, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Nautilus Biotechnology, Inc., headquartered in Seattle, Washington, is a life sciences company focused on developing a platform for single-molecule proteome analysis, aiming to transform proteomics and advance human health and medicine.
In its second quarter of 2025 financial results, Nautilus Biotechnology reported significant progress in its proteomic platform development, including the release of a scientific manuscript showcasing novel data and the signing of collaborations with major research institutes to explore Alzheimer’s disease.
Key financial highlights from the quarter include a reduction in operating expenses by 18% to $17.1 million, compared to the same period last year, attributed to cost optimization and decreased salaries and benefits. The company reported a net loss of $15.0 million, an improvement from the $18.0 million loss in the prior year. Nautilus holds $179.5 million in cash, cash equivalents, and investments as of June 30, 2025.
Looking ahead, Nautilus Biotechnology remains focused on advancing its proteomic platform and expanding its collaborations to enable groundbreaking research in proteomics, with the potential to significantly impact biomarker and therapeutic discovery.